Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Clover Health Investments enters the final stretch before its November 4 earnings with short sellers adding to positions for a second consecutive session, the stock up 9.4% on the week to $4.79, and retail attention running at its highest level in months.
Short interest continued to build on October 8, reaching 6.0% of the free float with 25.6 million shares short. That is up 6.3% in a single day and 4.6% over the week, extending the rebuild noted in yesterday's note. The borrow market remains entirely untroubled by this accumulation. Availability is running at around 820% of short interest, down about 9% on the week but still representing more than eight shares available for every one already borrowed. Cost to borrow is 0.50%, a level that remains near the low end of its recent range despite an 8% weekly rise and an 18% monthly drift higher. The ORTEX short score has ticked up to 49.3, its highest reading in the past ten days, but is still squarely in neutral territory. Nothing in the lending market points to squeeze pressure.
Options positioning is mildly more defensive than usual but not alarming. The put/call ratio is 0.27, slightly above its 20-day average of 0.25 and running about 1.2 standard deviations above that mean. The 52-week range for the PCR is 0.15 to 0.54, so the current reading is well within normal bounds. Wikipedia pageviews for Clover are generating a z-score of 1.7 against the stock's own 90-day history, a sign that retail attention is elevated. That is a sentiment and attention signal, not a financial data point, but it helps explain the momentum in the stock alongside short covering dynamics.
The Street's direction has been consistently upward on targets, even where conviction varies. UBS, holding a Neutral rating, raised its target to $5.00 after the August results. Canaccord Genuity's analyst has maintained a Buy through multiple target revisions and raised to $5.50 in July. The mean target of $5.375 sits about 12% above the current price of $4.79. The bull case rests on the Clover Assistant platform's ability to manage chronic disease costs and sustain improving unit economics. The bear case centres on a potential star-rating downgrade and flat CMS payment rates in 2027, which could pressure margins in a year when profitability is still relatively new. The EV/EBITDA multiple of 21.9x has compressed by roughly 3 points over the past month, a sign the stock's strong year-to-date run is being partially absorbed into valuation rather than simply re-rated higher. The 90-day forward EPS momentum factor scores in the 97th percentile, and analyst recommendation differential ranks in the 93rd, meaning the Street's direction of travel on this name is among the most positive in the sector.
Insider activity is worth noting in context. The CEO Andrew Toy sold 318,806 shares on October 1 for around $1.3 million, and the Medicare Advantage CEO Jamie Reynoso has made several smaller sales in recent weeks. All disclosed trades are under pre-arranged 10b5-1 plans, which means they were scheduled in advance and carry limited informational weight as signals of near-term conviction. Net insider sales over the past 90 days total roughly 948,000 shares valued at $4.3 million. On the institutional side, BlackRock added 3.3 million shares as of September 30, and both Vanguard's capital management arm and State Street added to positions in the same period. Nuveen added 2.6 million shares as of July 31. The pattern of institutional accumulation running alongside planned insider disposals is worth watching as the November print approaches.
What matters most over the next 25 days is whether the momentum in the stock, built on a 94% year-to-date advance and consistently improving EPS estimates, can survive a detailed look at the 2027 rate environment when the company reports on November 4.
See the live data behind this article on ORTEX.
Open CLOV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
